BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27621392)

  • 1. Perioperative Morbidity and Mortality Associated With Bleomycin in Primary Mediastinal Nonseminomatous Germ Cell Tumor.
    Ranganath P; Kesler KA; Einhorn LH
    J Clin Oncol; 2016 Dec; 34(36):4445-4446. PubMed ID: 27621392
    [No Abstract]   [Full Text] [Related]  

  • 2. Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy.
    Andrade RS; Kesler KA; Wilson JL; Brooks JA; Reichwage BD; Rieger KM; Einhorn LH; Brown JW
    Ann Thorac Surg; 2004 Oct; 78(4):1224-8; discussion 1228-9. PubMed ID: 15464475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum.
    Kesler KA; Kruter LE; Perkins SM; Rieger KM; Sullivan KJ; Runyan ML; Brown JW; Einhorn LH
    Ann Thorac Surg; 2011 Apr; 91(4):1085-93; discussion 1093. PubMed ID: 21440128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
    Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
    Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
    Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giant mediastinal germ cell tumor.
    Traibi A; Bakkali YE; Hammoumi ME; Kabiri el H
    Intern Med; 2011; 50(11):1261-2. PubMed ID: 21628948
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
    Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ
    Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
    Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of >20 years single institution experience.
    Géczi L; Budai B; Polk N; Fazekas F; Bodrogi I; Biró K
    Curr Probl Cancer; 2020 Aug; 44(4):100537. PubMed ID: 31980147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of combined modality therapy for patients with stage III or IV mediastinal malignant germ cell tumors.
    Kuwano H; Tsuchiya T; Murayama T; Sano A; Nagayama K; Yoshida Y; Murakawa T; Nakajima J
    Surg Today; 2014 Mar; 44(3):499-504. PubMed ID: 23553421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
    Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
    Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
    Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW
    Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
    Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the Australasian Germ Cell Trial Group: the management of advanced testis cancer.
    Raghavan D; Levi J; Thomson D; Harvey V
    Prog Clin Biol Res; 1990; 350():319-29. PubMed ID: 1696742
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.
    Yetisyigit T; Babacan N; Urun Y; Seber ES; Cihan S; Arpaci E; Yildirim N; Aksoy S; Budakoglu B; Zengin N; Oksuzoglu B; Yalcin BC; Alkis N
    Asian Pac J Cancer Prev; 2014; 15(2):831-5. PubMed ID: 24568504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors.
    Fein DE; Paulus JK; Mathew P
    JAMA Oncol; 2018 Dec; 4(12):1661-1662. PubMed ID: 30325997
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.